2-Picolinic Acid

2-Picolinic Acid

SCHEMBL6097337

O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5].[V+5]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.61
CES1 P23141 1/20 0.61
L3MBTL1 Q9Y468 3/20 0.59
LMNA P02545 3/20 0.59
P4HTM Q9NXG6 2/20 0.59
NAPRT Q6XQN6 1/20 0.59
ALDH1A1 P00352 1/20 0.57
KMT2A Q03164 2/20 0.53
GSK3B P49841 1/20 0.52
KDM4E B2RXH2 4/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Picolinic Acid SCHEMBL432468 0.98 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL11378795 0.96 CES2 (0.67) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL524041 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL11378797 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL15271681 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL5058098 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL15401421 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL5354659 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL432467 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL673572 0.93 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067527-B2 Thienopyridine derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
EP-1259515-B1 THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS TAKEDA PHARMACEUTICAL (JP) 2004-11-10 EP disclosed
US-20040054183-A1 Thienopyridine derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-18 US disclosed
US-6653476-B2 Antiinflammatory and antiarthritic agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-11-25 US disclosed
US-20030130517-A1 Thienopyridine derivatives , their production and use TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2003-07-10 US disclosed
EP-1259515-A2 THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-11-27 EP disclosed
WO-2001064685-A2 THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130517-A1 Thienopyridine derivatives , their production and use ALK, HRH2, TBXA2R CES2 3923/4885CES1 2753/4885L3MBTL1 4725/4885
US-20040054183-A1 Thienopyridine derivatives, their production and use ALK, HRH2, TBXA2R CES2 3923/4885CES1 2753/4885L3MBTL1 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.